Barclays’s Windtree Therapeutics Inc WINT Stock Holding History

Barclays’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-3,543	Closed	-$75K	–	7766
2013 Q2	$75K	Buy	+3,543	New	+$87.3K	﹤0.01%	6026

Other funds holding WINT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's WINT Position: Q3 2013 in Review

Barclays sold out of Windtree Therapeutics Inc (WINT) in Q3 2013, closing a stake of 3,543 shares — an estimated $75K sold.

Barclays first reported a position in WINT in Q2 2013 and held it in 1 quarter. The position peaked at $75K in Q2 2013. 50 funds tracked by Wall St. Rank hold WINT as of Q3 2013.

Barclays reported no remaining Windtree Therapeutics Inc position as of Q3 2013 after selling out during the quarter.
Barclays sold 3,543 Windtree Therapeutics Inc shares in Q3 2013, an estimated $75K.
Barclays first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 1 quarter.
Barclays's Windtree Therapeutics Inc position peaked at $75K in Q2 2013.
50 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q3 2013.

Based on Barclays's 13F filing for Q3 2013, filed 14 Nov 2013.